Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:

• Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)